Effect of PeakATP on Mood, Reaction Time and Cognition

NCT ID: NCT05100589

Last Updated: 2022-08-08

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 35 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-10-06
• Study Completion Date: 2022-04-19

Brief Summary

Oral ATP disodium (adenosine 5'- triphosphate disodium) is a commercially available product available alone and as a constituent in a number of sports supplements that is purported to maintain ATP levels and improve performance during high-intensity exercise. Acute deficits in cognitive performance have also been reported in both young adults and children following high-intensity exercise; however, the effects of supplemental ATP on cognitive performance has not been studied.

Goals:

1. To investigate the effect of ATP supplementation versus. placebo on mood, reaction time and cognitive performance before and after an acute bout of fatiguing exercise.

2. To investigate the effect of ATP supplementation versus. placebo on anaerobic performance.

Detailed Description

Oral ATP disodium (adenosine 5'- triphosphate disodium) is a commercially available product available alone and as a constituent in a number of sports supplements that is purported to maintain ATP levels during high-intensity exercise. Initial studies providing oral enteric coated ATP disodium displayed no apparent efficacy toward enhancing ATP levels, and subsequent research questioned the bioavailability of enteric coated ATP following oral administration (1,2). However, a recent study demonstrated that ingestion of 400mg uncoated ATP disodium for 15 days prevented decreases in ATP, adenosine diphosphate (ADP), and adenosine monophosphate (AMP) in the bloodstream for up to 30 minutes following high-intensity exercise when compared to placebo (3). Consistent with this, when oral ATP was administered in the form of non-coated ATP disodium, beneficial effects including reduced fatigue (3), improved strength, power, and body composition (5), and enhanced recovery (6) were observed.

Acute deficits in cognitive performance have also been reported in both young adults (6) and children (7) following high-intensity exercise. Cerebral activity is coupled to ATP metabolism, where energy flux is tightly correlated with energy demand (8). Thus, inadequate availability of metabolic resources may lead to acute or long-term cognitive impairments (9) and correspondingly, interventions that sustain ATP levels may have application for attenuating cognitive dysfunction in the face of an acute stressor that challenges brain energy metabolism. Notwithstanding, no study to date has examined the effect of uncoated ATP disodium supplementation on cognitive performance following high-intensity exercise.

Goals:

1. To investigate the the effects of uncoated ATP disodium (PeakATP) on mood (POMS - Profile of mood states questionnaire), psychological stress and cognition (ANAM - Automated Neuropsychological Assessment Metric), reaction time (RT - Dynavision D2 visuomotor tests), and multiple object tracking (MOT - Neurotracker)

2. To examine the effects of uncoated ATP disodium (PeakATP) on end power (mean power during last 30 seconds of 3-minute test), anaerobic working capacity (work above end power), peak power, mean power, time to peak power, fatigue slope (W/sec), rate of fatigue (%), and total work (joules) during a 3-minute all-out cycle ergometer test.

Method:

Randomized, double-blind, placebo controlled cross-over trial comparing the effect of supplementation with Peak ATP versus placebo on mood, reaction time and cognitive performance.

Supplementation will occur over a period of 14 days prior to completion of two separate experimental trials (randomly assigned), with a 14-day washout period in between. An acute dose will also be given during each experimental trial. POMS, RT, MOT and ANAM will be assessed pre- (0) immediately post- (IP) and 60-minutes (60P) post-completion of a 3-minute all-out cycle ergometer test. Anaerobic performance during the 3-minute test will be assessed.

Conditions

Cognitive Change; Mood

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: OTHER
• Blinding Strategy: DOUBLE

Study Groups

PeakATP

PeakATP formula dissolved in 8 ounces water, taken 30 minutes before breakfast on an empty stomach, or within 30 minutes of waking.

Group Type: EXPERIMENTAL

PeakATP

Intervention Type: DIETARY_SUPPLEMENT

Powder - 400mg Peak ATP, maltodextrin, silica-colloidal anhydrous, citric acid anhydrous, sucralose, guar gum

Placebo

Placebo formula (same as experimental with no PeakATP) dissolved in 8 ounces water, taken 30 minutes before breakfast on an empty stomach, or within 30 minutes of waking.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DIETARY_SUPPLEMENT

Powder - maltodextrin, silica-colloidal anhydrous, citric acid anhydrous, sucralose, guar gum

Interventions

PeakATP

Powder - 400mg Peak ATP, maltodextrin, silica-colloidal anhydrous, citric acid anhydrous, sucralose, guar gum

Intervention Type: DIETARY_SUPPLEMENT

Placebo

Powder - maltodextrin, silica-colloidal anhydrous, citric acid anhydrous, sucralose, guar gum

Intervention Type: DIETARY_SUPPLEMENT

Eligibility Criteria

Inclusion Criteria

• Healthy, and ready for physical activity as determined by physical activity readiness questionnaire (PAR-Q+) and medical history questionnaire (MHQ)
• Participants will be required to be recreationally-active (defined according to the American College of Sports Medicine (ACSM) standards of at least 150 minutes exercise per week)
• Participants must currently not be taking and be willing to abstain from creatine or beta-alanine supplementation or be willing to complete a 4-week wash-out period prior to enrolling if taking creatine or beta-alanine and be willing to abstain from supplementing with wither for the duration of the study. This will be verbally confirmed at the beginning of each visit.
• Participant understands the study procedures and signs forms providing informed consent to participate in the study.

Exclusion Criteria

• Individual does not provide consent to participate in this study.
• Inability to perform physical exercise (determined by MHQ and PAR Q+). That is Answering "Yes" to any question on the PAR-Q +, or having a pre-existing condition such as musculoskeletal injury, back pain, chronic pain etc. that the investigative team perceives will prevent a participant from safely completing the protocol.
• Not currently participating in at least 150 minutes of physical activity per week.
• Currently taking any performance-enhancing drug (determined from health and activity questionnaire)
• Currently taking a nutritional supplement known to improve anerobic performance that requires a wash-out period (e.g., creatine, beta-alanine) and are not willing to undergo a 4-week wash-out period prior to participating.
• Regularly taking any type of prescription or over-the-counter medication, or having any chronic illnesses, which require medical care
• Current known pregnancy

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 40 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

University of Central Florida

OTHER

Sponsor Role: lead

Responsible Party

Adam Wells

Associate Professor of Kinesiology

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Adam J Wells, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Central Florida

Locations

Kinesiology Research Labs

Orlando, Florida, United States

Countries

United States

References

Du F, Zhu XH, Zhang Y, Friedman M, Zhang N, Ugurbil K, Chen W. Tightly coupled brain activity and cerebral ATP metabolic rate. Proc Natl Acad Sci U S A. 2008 Apr 29;105(17):6409-14. doi: 10.1073/pnas.0710766105. Epub 2008 Apr 28.

Reference Type: BACKGROUND

PMID: 18443293 (View on PubMed)

Owen L, Sunram-Lea SI. Metabolic agents that enhance ATP can improve cognitive functioning: a review of the evidence for glucose, oxygen, pyruvate, creatine, and L-carnitine. Nutrients. 2011 Aug;3(8):735-55. doi: 10.3390/nu3080735. Epub 2011 Aug 10.

Reference Type: BACKGROUND

PMID: 22254121 (View on PubMed)

Arts IC, Coolen EJ, Bours MJ, Huyghebaert N, Stuart MA, Bast A, Dagnelie PC. Adenosine 5'-triphosphate (ATP) supplements are not orally bioavailable: a randomized, placebo-controlled cross-over trial in healthy humans. J Int Soc Sports Nutr. 2012 Apr 17;9(1):16. doi: 10.1186/1550-2783-9-16.

Reference Type: RESULT

PMID: 22510240 (View on PubMed)

Coolen EJ, Arts IC, Bekers O, Vervaet C, Bast A, Dagnelie PC. Oral bioavailability of ATP after prolonged administration. Br J Nutr. 2011 Feb;105(3):357-66. doi: 10.1017/S0007114510003570. Epub 2010 Dec 6.

Reference Type: RESULT

PMID: 21129239 (View on PubMed)

Purpura M, Rathmacher JA, Sharp MH, Lowery RP, Shields KA, Partl JM, Wilson JM, Jager R. Oral Adenosine-5'-triphosphate (ATP) Administration Increases Postexercise ATP Levels, Muscle Excitability, and Athletic Performance Following a Repeated Sprint Bout. J Am Coll Nutr. 2017 Mar-Apr;36(3):177-183. doi: 10.1080/07315724.2016.1246989. Epub 2017 Jan 12.

Reference Type: RESULT

PMID: 28080323 (View on PubMed)

Rathmacher JA, Fuller JC Jr, Baier SM, Abumrad NN, Angus HF, Sharp RL. Adenosine-5'-triphosphate (ATP) supplementation improves low peak muscle torque and torque fatigue during repeated high intensity exercise sets. J Int Soc Sports Nutr. 2012 Oct 9;9(1):48. doi: 10.1186/1550-2783-9-48.

Reference Type: RESULT

PMID: 23046855 (View on PubMed)

Wilson JM, Joy JM, Lowery RP, Roberts MD, Lockwood CM, Manninen AH, Fuller JC, De Souza EO, Baier SM, Wilson SM, Rathmacher JA. Effects of oral adenosine-5'-triphosphate supplementation on athletic performance, skeletal muscle hypertrophy and recovery in resistance-trained men. Nutr Metab (Lond). 2013 Sep 22;10(1):57. doi: 10.1186/1743-7075-10-57.

Reference Type: RESULT

PMID: 24330670 (View on PubMed)

de Freitas MC, Ricci-Vitor AL, Freire RV, Caperuto EC, Vanderlei LCM, Lira FS, Rossi FE. Oral adenosine 5'-triphosphate supplementation improved hemodynamic and autonomic parameters after exercise in hypertensive women. J Exerc Rehabil. 2018 Aug 24;14(4):671-679. doi: 10.12965/jer.1836256.128. eCollection 2018 Aug.

Reference Type: RESULT

PMID: 30276192 (View on PubMed)

Sun S, Loprinzi PD, Guan H, Zou L, Kong Z, Hu Y, Shi Q, Nie J. The Effects of High-Intensity Interval Exercise and Hypoxia on Cognition in Sedentary Young Adults. Medicina (Kaunas). 2019 Feb 10;55(2):43. doi: 10.3390/medicina55020043.

Reference Type: RESULT

PMID: 30744172 (View on PubMed)

Samuel RD, Zavdy O, Levav M, Reuveny R, Katz U, Dubnov-Raz G. The Effects of Maximal Intensity Exercise on Cognitive Performance in Children. J Hum Kinet. 2017 Jun 22;57:85-96. doi: 10.1515/hukin-2017-0050. eCollection 2017 Jun.

Reference Type: RESULT

PMID: 28713461 (View on PubMed)

Other Identifiers

STUDY00003272

Identifier Type: -

Identifier Source: org_study_id